Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, Savoie ML, Bahlis NJ, Brown C, Storek J, Andersson BS, Russell JA. Geddes M, et al. Among authors: kangarloo sb. Biol Blood Marrow Transplant. 2008 Feb;14(2):220-8. doi: 10.1016/j.bbmt.2007.10.028. Biol Blood Marrow Transplant. 2008. PMID: 18215782 Free article. Clinical Trial.
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.
Russell JA, Kangarloo SB, Williamson T, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Shafey M, Brown CB, Yang M, Geddes M, Zacarias N, Yue P, Duggan P, Stewart DA, Daly A. Russell JA, et al. Among authors: kangarloo sb. Biol Blood Marrow Transplant. 2013 Sep;19(9):1381-6. doi: 10.1016/j.bbmt.2013.07.002. Epub 2013 Jul 17. Biol Blood Marrow Transplant. 2013. PMID: 23871781 Free article.
Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function.
Griffiths CD, Ng ES, Kangarloo SB, Williamson TS, Chaudhry MA, Booker R, Duggan P, Yue P, Savoie L, Brown C, Cox-Kennett N, Russell JA, Daly A, Storek J. Griffiths CD, et al. Among authors: kangarloo sb. Bone Marrow Transplant. 2014 Apr;49(4):589-91. doi: 10.1038/bmt.2013.234. Epub 2014 Jan 27. Bone Marrow Transplant. 2014. PMID: 24464143 No abstract available.
Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB, Naveed F, Ng ES, Chaudhry MA, Wu J, Bahlis NJ, Brown CB, Daly A, Duggan P, Geddes M, Quinlan D, Savoie ML, Shafey M, Stewart DA, Storek J, Yang M, Zacarias N, Yue P, Magliocco AM, Russell JA. Kangarloo SB, et al. Biol Blood Marrow Transplant. 2012 Feb;18(2):295-301. doi: 10.1016/j.bbmt.2011.07.015. Epub 2011 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 21801704 Free article. Clinical Trial.
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin.
Dabas R, Jamani K, Kangarloo SB, Dharmani-Khan P, Williamson TS, Ousia S, Durand C, Morris D, Mahoney D, Savoie L, Chaudhry A, Jimenez-Zepeda VH, Khan FM, Daly A, Storek J. Dabas R, et al. Among authors: kangarloo sb. Blood Adv. 2019 May 14;3(9):1394-1405. doi: 10.1182/bloodadvances.2018030247. Blood Adv. 2019. PMID: 31043372 Free PMC article.
14 results